Company Overview
Snapshot
Founded in November 2020, Cardionyx Heart Science operates with 1–10 employees. The company has raised $700,000 across one funding round. In August 2023, Cardionyx secured SAFE funding, signaling continued development in its medical device technology.
Business overview
Cardionyx Heart Science is a medical innovation company developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients with reduced ejection fraction (HFrEF). Its core technology involves a trans-vessel active implant designed for minimally invasive procedures, leveraging venous catheterization for implantation. The implant provides personalized therapy through real-time hemodynamic monitoring, allowing dynamic regulation of parasympathetic tone to maximize efficacy and minimize adverse events. Cardionyx operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers and patients in markets including North America and the Americas.
Strategic signal
In August 2021, Cardionyx Heart Science was recognized by TechTimes as one of the 'Top 5 HealthTech Startups That Are Experts in Heart Failure.' This highlights the company's early market recognition and validates its innovative approach to addressing critical clinical needs in heart failure treatment, signaling potential for significant impact within the cardiovascular medical device industry.
Log in to access full profile ›Company Intelligence Q&A
- What is Cardionyx Heart Science's primary focus?
- Cardionyx Heart Science is focused on developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, particularly those with reduced ejection fraction (HFrEF).
- When was Cardionyx Heart Science founded?
- Cardionyx Heart Science was founded in November 2020.
- What is the total funding raised by Cardionyx Heart Science?
- Cardionyx Heart Science has raised a total of $700,000 across one funding round. Their latest funding was a SAFE round in August 2023.
- What was a significant recent development for Cardionyx Heart Science?
- In August 2023, Cardionyx Heart Science secured SAFE funding, supporting its ongoing development in medical device technology.
- Which markets does Cardionyx Heart Science target?
- Cardionyx Heart Science targets geomarkets in North America and the Americas.